Highlights of PAPR Inhibitors in Small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2020.102.19
- Author:
Shuang ZHANG
1
;
Jingjing LIU
1
;
Changliang YANG
1
;
Liang ZHANG
1
;
Shuang LI
1
;
Hao BAO
1
;
Ying CHENG
1
Author Information
1. Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
PARP inhibitor
- From:
Chinese Journal of Lung Cancer
2020;23(9):806-810
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC), characterized by early metastasis, relapse, relapse and resistance and poor prognosis, still faces difficulties in treatment. Recently, Immunotherapy is a novel treatment for SCLC, researchers are also eager to achieve a breakthrough in targeted treatment of SCLC. Genomic instability of SCLC and sensitivity to cytotoxic chemotherapy, therefore, poly ADP-ribose polymerase (PARP) inhibitors targeting DNA repair related pathways have become a hotspot in the research of SCLC targeted therapy. Studies on PARP inhibitors in SCLC have been conducted in combination with other therapeutic strategies, including the treatment of recurrent SCLC and first-line treatment,as well as maintenance treatment after induction. These studies also explored the predictive markers of PARP inhibitors in SCLC. Although the current results of PARP inhibitors in SCLC are limited, and the predictive markers are also inconsistent, we also see that PARP inhibitors could be a breakthroughfor precision medicine of SCLC.
.
